Research - The regulatory and legislative environment has improved dramatically in the last half-decade for antibiotics developers, with some new incentives still in the works, and we … Continue Reading
Read nowResearch - – Despite post-earnings selloff, longterm outlook remains intact. MDVN is an attractive part of a core healthcare portfolio. – Off-putting 2014 Xtandi guidance may prove … Continue Reading
PremiumInsights - Alexion (ALXN) raised guidance this week with reimbursement news from France. Here's more on the company's 2014.
Read nowResearch - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year, with shares rising over 187% since our July 2013 initiation of … Continue Reading
PremiumResearch - Update after the bell, BioLife announces a 1:14 reverse split. Talk about timing. BioLife Solutions (BLFS) (which Mr. Deryugin wrote about this morning below and in advance … Continue Reading
Read nowResearch - Since our initial report on Pharmacyclics (PCYC) on February 11, shares of the oncology company have returned almost 52%. Pharmacyclics’ relative underperformance to the NASDAQ … Continue Reading
Read nowResearch - Since we last profiled Cubist Pharmaceuticals (CBST) in August, shares of the antibiotics company have posted a somewhat muted performance, rising less than 8% versus … Continue Reading
Read now
